Experimental Anti-cancer Synthetic Molecule Targets Tumor Cell Growth And Angiogenesis
Thursday, June 19, 2008 - 21:28
in Health & Medicine
A recent study describes a new candidate anti-cancer drug, HB-19. In contrast to conventional anti-cancer drugs, HB-19 has a dual mechanism of action by independently targeting tumor cell growth and tumor. The molecular target of HB-19 is nucleolin expressed on the surface of all activated cells, in particular rapidly growing tumor cells and endothelial cells that play a key role in angiogenesis.